دورية أكاديمية
أعرض في EDS

Knockdown of TPI in human dermal microvascular endothelial cells and its impact on angiogenesis in vitro.

التفاصيل البيبلوغرافية
العنوان: Knockdown of TPI in human dermal microvascular endothelial cells and its impact on angiogenesis in vitro.
المؤلفون: Herre C; Institute of Veterinary Anatomy, School of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany., Nshdejan A; Institute of Veterinary Anatomy, School of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany., Klopfleisch R; Institute of Veterinary Pathology, School of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany., Corte GM; Department of Veterinary Medicine, Institute of Veterinary Anatomy, Universität Zürich, Zurich, Switzerland., Bahramsoltani M; Institute of Veterinary Anatomy, School of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany.
المصدر: PloS one [PLoS One] 2023 Dec 20; Vol. 18 (12), pp. e0294933. Date of Electronic Publication: 2023 Dec 20 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Triose-Phosphate Isomerase*/genetics , Endothelial Cells*/metabolism, Humans ; Reproducibility of Results ; Angiogenesis ; Down-Regulation ; Methionine Adenosyltransferase/metabolism
مستخلص: Introduction: Angiogenic behaviour has been shown as highly versatile among Endothelial cells (ECs) causing problems of in vitro assays of angiogenesis considering their reproducibility. It is indispensable to investigate influencing factors of the angiogenic potency of ECs.
Objective: The present study aimed to analyse the impact of knocking down triosephosphate isomerase (TPI) on in vitro angiogenesis and simultaneously on vimentin (VIM) and adenosylmethionine synthetase isoform type 2 (MAT2A) expression. Furthermore, native expression profiles of TPI, VIM and MAT2A in the course of angiogenesis in vitro were examined.
Methods: Two batches of human dermal microvascular ECs were cultivated over 50 days and stimulated to undergo angiogenesis. A shRNA-mediated knockdown of TPI was performed. During cultivation, time-dependant morphological changes were detected and applied for EC-staging as prerequisite for quantifying in vitro angiogenesis. Additionally, mRNA and protein levels of all proteins were monitored.
Results: Opposed to native cells, knockdown cells were not able to enter late stages of angiogenesis and primarily displayed a downregulation of VIM and an uprise in MAT2A expression. Native cells increased their TPI expression and decreased their VIM expression during the course of angiogenesis in vitro. For MAT2A, highest expression was observed to be in the beginning and at the end of angiogenesis.
Conclusion: Knocking down TPI provoked expressional changes in VIM and MAT2A and a deceleration of in vitro angiogenesis, indicating that TPI represents an angiogenic protein. Native expression profiles lead to the assumption of VIM being predominantly relevant in beginning stages, MAT2A in beginning and late stages and TPI during the whole course of angiogenesis in vitro.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2023 Herre et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
References: Microcirculation. 2014 May;21(4):333-44. (PMID: 24387004)
J Cell Biol. 2003 Jun 23;161(6):1163-77. (PMID: 12810700)
Cell Mol Life Sci. 2022 Jun 7;79(7):349. (PMID: 35672585)
Exp Cell Res. 2010 Jan 15;316(2):172-80. (PMID: 19715692)
Biochim Biophys Acta. 2009 Dec;1792(12):1168-74. (PMID: 19786097)
Cell Mol Life Sci. 2010 Dec;67(23):3961-82. (PMID: 20694739)
ALTEX. 2004;21(4):227-44. (PMID: 15586254)
Am J Physiol Cell Physiol. 2010 Aug;299(2):C363-73. (PMID: 20427712)
Arch Biochem Biophys. 2004 Mar 15;423(2):332-42. (PMID: 15001397)
Nat Cell Biol. 2010 Oct;12(10):943-53. (PMID: 20871601)
Biochimie. 2022 Jun;197:96-112. (PMID: 35151830)
Int J Exp Pathol. 2009 Jun;90(3):195-221. (PMID: 19563606)
Hepatology. 2009 Aug;50(2):462-71. (PMID: 19444874)
J Cell Sci. 2003 Dec 15;116(Pt 24):4977-84. (PMID: 14625391)
Annu Rev Cell Dev Biol. 2011;27:441-64. (PMID: 21985671)
Biochem J. 2013 May 15;452(1):27-36. (PMID: 23425511)
J Am Chem Soc. 2017 Oct 4;139(39):13754-13760. (PMID: 28880543)
Methods Mol Biol. 2016;1464:185-191. (PMID: 27858367)
FASEB J. 2021 Jun;35(6):e21612. (PMID: 33948996)
Science. 2002 Feb 1;295(5556):868-72. (PMID: 11786607)
Int J Mol Sci. 2020 Mar 28;21(7):. (PMID: 32231163)
PLoS Biol. 2007 Dec;5(12):e321. (PMID: 18052609)
PLoS One. 2015 Jan 24;10(1):e0115853. (PMID: 25617624)
Bioessays. 2020 Nov;42(11):e2000078. (PMID: 32893352)
Clin Hemorheol Microcirc. 2011;48(1):15-27. (PMID: 21876231)
Curr Protein Pept Sci. 2019;20(4):304-315. (PMID: 30370845)
Biol Pharm Bull. 2007 Feb;30(2):247-53. (PMID: 17268060)
Anim Nutr. 2018 Mar;4(1):11-16. (PMID: 30167479)
Clin Hemorheol Microcirc. 2010;46(2-3):189-202. (PMID: 21135494)
Mol Biol Rep. 2021 Jan;48(1):941-950. (PMID: 33393005)
J Med Chem. 2022 Jul 28;65(14):9531-9547. (PMID: 35796517)
Dev Biol. 2012 Dec 15;372(2):157-65. (PMID: 23031691)
PLoS One. 2022 Apr 28;17(4):e0266774. (PMID: 35482724)
Cells. 2018 Sep 21;7(10):. (PMID: 30248895)
Biomedicines. 2019 May 16;7(2):. (PMID: 31100863)
Clin Hemorheol Microcirc. 2013 Jan 1;55(2):255-69. (PMID: 23089887)
Angiogenesis. 2018 Aug;21(3):425-532. (PMID: 29766399)
Nature. 1997 Apr 17;386(6626):671-4. (PMID: 9109485)
Biomedicines. 2021 Feb 03;9(2):. (PMID: 33546224)
Cancer Metastasis Rev. 2010 Dec;29(4):655-76. (PMID: 20821252)
Cells. 2022 Jan 25;11(3):. (PMID: 35159219)
APMIS. 2007 Jan;115(1):30-46. (PMID: 17223849)
Trends Endocrinol Metab. 2020 Aug;31(8):580-595. (PMID: 32622584)
Mol Med. 2023 Jan 31;29(1):18. (PMID: 36721084)
Saudi Pharm J. 2015 Jul;23(3):223-9. (PMID: 26106269)
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4574-E4581. (PMID: 28533359)
Sci Rep. 2019 Jul 18;9(1):10414. (PMID: 31320669)
المشرفين على المادة: EC 5.3.1.1 (Triose-Phosphate Isomerase)
EC 2.5.1.6 (MAT2A protein, human)
EC 2.5.1.6 (Methionine Adenosyltransferase)
تواريخ الأحداث: Date Created: 20231220 Date Completed: 20231222 Latest Revision: 20231223
رمز التحديث: 20231223
مُعرف محوري في PubMed: PMC10732452
DOI: 10.1371/journal.pone.0294933
PMID: 38117832
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0294933